Immunic, Inc.
NASDAQ:IMUXBiotechnology
-$0.04 today
- Market cap
- $102.61M
- Beta
- 1.39
- P/E (TTM)
- -4.1
- EPS (TTM)
- -$3.46
Volume 0.17M
Average 0.27M
IMUX Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Immunic, Inc.NASDAQ: IMUX
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue remains negative
Q1 FY2026 cost of revenue was $33K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $33K.
Context
- Cost of revenue increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly cost of revenue holds near $33K or moves back toward the trailing-twelve-month quarterly average of $8.25K.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Cost of Revenue vs competitors
How IMUX compares with its peers on the latest reported figures
- IMUX's LTM Mar 2026 cost of revenue of $33K is the 6th highest of the 9 companies compared; the peer median is $329.5K.
- Its year-over-year change of -50.0% is the 2nd highest of 4, against a peer median of -82.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.34M | — | — | — | |
CBUSCibus, Inc. | LTM Mar 2026 | $1.2M | -30.9% | +56.9% | 27.9% |
| LTM Mar 2026 | $693K | — | — | 7.6% | |
| LTM Mar 2026 | $593K | — | — | — | |
| LTM Mar 2026 | $66K | -82.3% | — | — | |
| LTM Mar 2026 | $33K | -50.0% | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$228K | -137.1% | — | — |
| Peer median (excluding IMUX) | $329.5K | -82.3% | +56.9% | 7.6% | |
Competitors are the stored peer set for IMUX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 61.12M | 71.26M | 83.22M | 80.05M | 81.98M |
| Selling, General & Admin | 13.3M | 15.26M | 16.01M | 18.01M | 21.25M |
| Operating Expenses | 91.67M | 119.49M | 99.22M | 98.05M | 103.23M |
| Depreciation & Amortization | 85K | 77K | 111K | 134K | 168K |
| EBITDA | (92.86M) | (86.44M) | (93.5M) | (100.37M) | (97M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (91.67M) | (119.49M) | (99.22M) | (98.05M) | (103.23M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 66K | 1.04M | 3.08M | 3.39M | 1.04M |
| Interest Expense | 0 | 1.04M | 0 | 0 | 0 |
| Other Income / Expenses | (1.28M) | (919K) | 5.61M | (2.46M) | 6.06M |
| Income Before Tax | (92.95M) | (120.41M) | (93.61M) | (100.51M) | (97.17M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (92.95M) | (120.41M) | (93.61M) | (100.51M) | (97.17M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (39.20) | (37.80) | (21.10) | (10.00) | (6.24) |
| EPS (Diluted) | (39.20) | (37.80) | (21.10) | (10.00) | (6.24) |
| Weighted Avg Shares | 2.37M | 3.18M | 4.43M | 10.02M | 15.57M |
| Weighted Avg Shares (Diluted) | 2.37M | 3.18M | 4.43M | 10.02M | 15.57M |
Immunic, Inc.
NASDAQ:IMUX
Intrinsic Alpha fair value
Locked
Current Price
$7.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.